RecruitingNCT03200379

Nation-wide Hepatitis C Virus (HCV) Registry in Taiwan

Sponsor

Kaohsiung Medical University Chung-Ho Memorial Hospital

Enrollment

150,000 participants

Start Date

Jun 15, 2017

Study Type

OBSERVATIONAL

Conditions

Hepatitis C, Chronic

Summary

To determine the treatment efficacy, safety and long-term outcomes of chronic hepatitis C patients receiving directly acting antivirals in Taiwan

Eligibility

Inclusion Criteria1

\. Patients who are treated with DAA and have willingness to participate in this registry.

Exclusion Criteria1

Chronic hepatitis C patients who are unwilling to participate in the study and do not provide written informed consent for participation.

Interventions

OTHERdirectly acting antivirals (DAAs)

Eligible subjects would be those CHC patients who receive approved DAA in the daily practice in Taiwan. No clinical developing medications will be allocated patients.

Locations(1)

HepatobiliaryDivision, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

Kaohsiung City, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03200379

Related Trials

Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy

NCT051409419 locations

C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV

NCT0703727789 locations

Treating Hepatitis C in Pakistan. Strategies to Avoid Resistance to Antiviral Drugs

NCT049435881 location

Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)

NCT058709691 location